A Phase 3 Trial of Bevacizumab in Ovarian Cancer
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
About this item
Full title
Author / Creator
ICON7 Investigators , Perren, Timothy J , Swart, Ann Marie , Pfisterer, Jacobus , Ledermann, Jonathan A , Pujade-Lauraine, Eric , Kristensen, Gunnar , Carey, Mark S , Beale, Philip , Cervantes, Andrés , Kurzeder, Christian , Bois, Andreas du , Sehouli, Jalid , Kimmig, Rainer , Stähle, Anne , Collinson, Fiona , Essapen, Sharadah , Gourley, Charlie , Lortholary, Alain , Selle, Frédéric , Mirza, Mansoor R , Leminen, Arto , Plante, Marie , Stark, Dan , Qian, Wendi , Parmar, Mahesh K.B and Oza, Amit M
Publisher
Waltham, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Waltham, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
The addition of bevacizumab to chemotherapy (15 mg/kg for six cycles) followed by extended therapy with bevacizumab every 3 weeks for a total of 15 months of treatment improved progression-free survival by 4 months in incompletely resected stage III or IV ovarian cancer.
Ovarian cancer is the fourth most common cause of cancer-related deaths in...
Alternative Titles
Full title
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Authors, Artists and Contributors
Author / Creator
Perren, Timothy J
Swart, Ann Marie
Pfisterer, Jacobus
Ledermann, Jonathan A
Pujade-Lauraine, Eric
Kristensen, Gunnar
Carey, Mark S
Beale, Philip
Cervantes, Andrés
Kurzeder, Christian
Bois, Andreas du
Sehouli, Jalid
Kimmig, Rainer
Stähle, Anne
Collinson, Fiona
Essapen, Sharadah
Gourley, Charlie
Lortholary, Alain
Selle, Frédéric
Mirza, Mansoor R
Leminen, Arto
Plante, Marie
Stark, Dan
Qian, Wendi
Parmar, Mahesh K.B
Oza, Amit M
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_913061140
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_913061140
Other Identifiers
ISSN
0028-4793,1533-4406
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1103799
